# CTU COVID Testing Supplement

> **NIH NIH UM1** · EMORY UNIVERSITY · 2020 · $599,941

## Abstract

Emory-CDC Clinical Trials Unit-Supplement for COVID-19 testing
Project Summary/Abstract
The emerging COVID-19 pandemic, caused by the SARS-Co-V-2 coronavirus has already caused over 1.3
million infections and over 80,000 deaths in the US as of May 13, 2020 (1). In the absence of effective
therapies or a vaccine, non-pharmacologic measures such as social distancing, face masks and lockdowns
have been implemented for prevention of COVID-19 infection which has helped to decrease the spread.
Additional critical measures to control the pandemic include identification and isolation of infected individuals
and contact tracing which requires scaling up of testing for all people. As of May 13, 2020, the US has been
able to perform ~ 9 million tests, or around 29,000 tests/million population. While this is a large number and, in
fact, more tests performed than any other country in the world, it is still not sufficient. Several investigators
suggest that 3 – 4 million tests/week are needed in order to test ~ 1% of the US population.
Atlanta, Georgia has not been spared by the COVID-19 pandemic. While these is no data available for City of
Atlanta, the 5 counties that form the Atlanta metropolitan area (Fulton, DeKalb, Gwinnett, Clayton and Cobb)
have reported 11,771 cases which represents 34% of the total cases reported in the State of Georgia (2). The
characteristics and clinical outcomes of hospitalized patients with COVID-19 in Georgia have been recently
described (3). Among 305 patients, the median age was 60 years with 29% of the patients under the age of 50.
Also, 83% were African American and although co-morbid conditions such as diabetes, obesity and
hypertension were common, 1 in 4 patients admitted did not have any high-risk conditions. In a study among
COVID-19 patients in three hospitals where Emory University faculty provide medical care, 20 of 530 persons
had HIV co-infection. Median age was 57 years, most had controlled HIV and comorbid condition such as
hypertension and diabetes.
The Emory-CDC HIV Clinical Trials Unit has two Clinical Research Sites in Atlanta, the Hope Clinic of the
Emory Vaccine Center and the Ponce de Leon Clinic. Both sites offer great opportunities to expand testing,
not only to their existing patient populations but also to the neighboring communities. In this application we
propose to use the existing infrastructure for research and will add expanded facilities for COVID-19 testing.
Since testing for COVID-19 must incorporate safety measures for the staff, we plan to develop expanded
facilities including temporary tents to accommodate potential drive through scenarios, and/or a mobile health
clinic.

## Key facts

- **NIH application ID:** 10166198
- **Project number:** 3UM1AI069418-14S1
- **Recipient organization:** EMORY UNIVERSITY
- **Principal Investigator:** Jeffrey Lennox
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $599,941
- **Award type:** 3
- **Project period:** 2020-06-16 → 2021-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10166198

## Citation

> US National Institutes of Health, RePORTER application 10166198, CTU COVID Testing Supplement (3UM1AI069418-14S1). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10166198. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*